Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Open-label, Phase I/III Study Investigating Pharmacokinetic Properties of BT524 and Efficacy and Safety of BT524 in the Treatment and Prophylaxis of Bleeding in Patients With Congenital Fibrinogen Deficiency

NCT02065882 is registered in ClinicalTrials.gov with Biotest as lead sponsor.

NCT NCT02065882
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02065882 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Open-label, Phase I/III Study Investigating Pharmacokinetic Properties of BT524 and Efficacy and Safety of BT524 in the Treatment and Prophylaxis of Bleeding in Patients With Congenital Fibrinogen Deficiency
Lead sponsor
Biotest
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2013
Completion date
November 18, 2020
Enrollment
67 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

congenital afibrinogenemia, congenital hypofibrinogenemia